Apollo Endosurgery (NASDAQ:APEN) is set to issue its quarterly earnings data before the market opens on Monday, March 18th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.
Shares of NASDAQ:APEN opened at $3.32 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.42 and a quick ratio of 1.81. The stock has a market cap of $71.59 million, a price-to-earnings ratio of -1.65 and a beta of 0.72. Apollo Endosurgery has a 1-year low of $3.02 and a 1-year high of $9.65.
In other news, major shareholder Stonepine Capital, L.P. sold 250,000 shares of the company’s stock in a transaction dated Thursday, December 27th. The stock was sold at an average price of $3.00, for a total value of $750,000.00. Following the completion of the sale, the insider now directly owns 2,185,426 shares of the company’s stock, valued at approximately $6,556,278. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 52.80% of the company’s stock.
APEN has been the subject of a number of recent analyst reports. Zacks Investment Research cut Apollo Endosurgery from a “hold” rating to a “sell” rating in a research note on Friday, December 21st. Northland Securities raised Apollo Endosurgery from an “under perform” rating to a “market perform” rating and set a $3.00 price target for the company in a research note on Wednesday, January 2nd. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Apollo Endosurgery has a consensus rating of “Hold” and an average target price of $4.69.
About Apollo Endosurgery
Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices. It develops and distributes devices for minimally invasive surgical and non-surgical bariatric and gastrointestinal procedures that are used by surgeons and gastroenterologists in various settings to provide interventional therapy to patients who suffer from obesity and various co-morbidities associated with obesity, as well as treat various other gastrointestinal conditions.
Further Reading: Stock Selection – What is cash flow?
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.